The stock is a binary catalyst play on BLA submission and FDA feedback. Key near-term catalysts: topline OL data (any day now), Type B FDA meeting outcome, and rolling BLA initiation in June. The $200.4M cash runway removes near-term financing risk. Watch for any FDA pushback on the surrogate endpoint or safety database adequacy, that would be a major negative. The 7 anaphylaxis cases in the OL study (out of 39) remain a safety overhang for the BLA review.
LRMR drugs
LRMR drug pipeline →Price Chart
Executive Summary
Larimar Therapeutics reported Q1 2026 net loss of $29.6M ($0.31/share), roughly in line with the $29.3M loss in Q1 2025, with no revenue. The filing highlights continued FDA alignment for a rolling BLA submission seeking accelerated approval for nomlabofusp in Friedreich's ataxia, with nonclinical/clinical modules planned for June 2026 and CMC module in 2H 2026. Cash position strengthened to $200.4M (post-February $107.6M net offering), extending runway into Q2 2027. The stock will move on upcoming binary catalysts: topline open-label data (Q2 2026), Type B FDA meeting, and BLA submission progress.
Key Financial Metrics
Key Facts
- Q1 2026 net loss $29.6M ($0.31/share) vs $29.3M ($0.46/share) in Q1 2025, loss per share improved on higher share count
- Cash, cash equivalents and marketable securities of $200.4M as of March 31, 2026, with projected runway into Q2 2027
- Planning rolling BLA submission seeking accelerated approval: nonclinical/clinical modules June 2026, CMC module 2H 2026
- Type B meeting with FDA scheduled later in Q2 2026 to align on BLA data package readiness
- Topline open-label study data expected Q2 2026; first patient dosing in global Phase 3 confirmatory study expected mid-2026
- Breakthrough Therapy Designation granted February 2026; FDA aligned on FXN as surrogate endpoint
- February 2026 public offering raised $107.6M net proceeds; 103.9M shares outstanding as of March 31, 2026 (up from 83.1M at Dec 31, 2025)
- No revenue; pre-revenue clinical-stage biotech
Financial Impact
No revenue; net loss $29.6M in Q1 2026; cash burn rate ~$10M/month; $200.4M cash runway into Q2 2027
Risk Factors
- FDA may not accept FXN as a surrogate endpoint for accelerated approval, BLA submission could be delayed or require additional data
- 7 of 39 OL study participants experienced anaphylaxis, safety database adequacy will be reviewed at BLA submission
- Rolling BLA strategy is pending FDA feedback from Type B meeting, could change if FDA disagrees
- No approved product; pre-revenue with history of net losses; dilution risk from additional capital raises
- Competing therapies (Skyclarys/omaveloxolone) already approved for FA, though they do not address frataxin deficiency
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-222746 |
| Document: lrmr-ex99_2.htm | 0001193125-26-222746 |
| Document: lrmr-20260514.htm | 0001193125-26-222746 |
| Document: 0001193125-26-222746-index-headers.html | 0001193125-26-222746 |
| Document: 0001193125-26-222746-index.html | 0001193125-26-222746 |
| Document: 0001193125-26-222746.txt | 0001193125-26-222746 |
| 8-K Data (Synthetic) | 0001193125-26-222746 |
Track record
13 reports on LRMR
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +36.13% at T+20 after the Sep 22, 2026 report. 3 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $3.00 Now $3.00 0.00% settles Feb 12
- Nov 16, 2026today Press Release Bullish 7/10 Entry $3.10 Now $3.00 −3.23% settles Feb 12
- Nov 12, 20264d ago Insider Cluster Bullish 4/10 Entry $3.02 Now $3.00 −0.66% settles Feb 11
- Nov 9, 20267d ago 8-K Bullish 7/10 Entry $2.69 Now $3.00 +11.52% settles Feb 8
- Nov 5, 202611d ago Press Release Neutral 2/10 Entry $2.39 Now $3.00 +25.52% settles Feb 4
- Sep 29, 20266w ago Press Release Neutral 3/10 Entry $3.20 Now $3.00 −6.10% settles Dec 24
- Sep 22, 20267w ago Institutional Cluster Bearish 4/10 Entry $3.82 Now $3.00 +21.47% settles Dec 16
- May 14, 202626w ago 8-K Bullish 7/10 Viewing No price data
- May 14, 202626w ago Press Release Bullish 7/10 Entry $3.89 to $4.01 Now $3.00 −22.88% ▲ +3.08% −0.50% vs SPY
- Mar 19, 202634w ago Press Release Mixed 7/10 Entry $4.47 to $3.59 Now $3.00 −32.89% ▼ −19.69% −34.03% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers